US Edition
Seaport Therapeutics doses first patient in trial of GlyphAllo for depression - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Seaport Therapeutics doses first patient in trial of GlyphAllo for depression - Pharmafile
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of allopregnanolone, for the treatment of major depressive disorder (MDD), with or without anxious distress. GlyphAllo is designed using the company’s Glyph platform to overcome bioavailability limitations of allopregnanolone, a molecule known for its rapid antidepressant […] The post Seaport Therapeutics doses first patient in t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium